EMA Withdrawn: Vibativ (telavancin) — Theravance Biopharma Ireland Umited

View source ↗

Summary

The EMA has withdrawn Vibativ (telavancin) from the market in the EU, a drug indicated for bacterial pneumonia and cross-infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Pneumonia
• Cross Infection

Drugs mentioned

• Vibativ (telavancin)

Snippet

Status: Withdrawn. Therapeutic area: Pneumonia, Bacterial;Cross Infection. MAH: Theravance Biopharma Ireland Umited. Decision date: 08/09/2017